
AI is about to change healthcare. These 32 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
To own RLI, you generally need to believe in its ability to sustain disciplined underwriting, manage catastrophe exposure, and convert that into solid, if volatile, earnings. The new 5.375% notes due 2036 and larger credit facility mainly strengthen liquidity; they do not materially change the near term balance between the key catalyst of underwriting performance and the biggest risk of margin pressure from catastrophes, competition, and rising expenses.
Among recent announcements, the board’s decision on 18 February 2026 to maintain the regular quarterly dividend at US$0.16 per share stands out alongside the new debt deal. Together, a steady dividend and extended-term funding frame RLI as prioritizing balance sheet flexibility and consistent shareholder returns, which matters if underwriting results soften or if higher technology and acquisition costs weigh on near term profitability.
Yet beneath the reassuring liquidity and dividends, investors should be aware that catastrophe risk and expense inflation could still...
Read the full narrative on RLI (it's free!)
RLI's narrative projects $1.9 billion revenue and $297.9 million earnings by 2028.
Uncover how RLI's forecasts yield a $59.75 fair value, a 3% downside to its current price.
The most optimistic analysts were assuming RLI could reach roughly US$1.9 billion of revenue and about US$346 million of earnings by 2028, so compared with the consensus focus on margin pressure and flat revenue, they present a much more upbeat story that you should weigh carefully against this new debt issuance and the risk of concentrated losses in RLI’s niche lines.
Explore 2 other fair value estimates on RLI - why the stock might be worth just $59.75!
Don't just follow the ticker - dig into the data and build a conviction that's truly your own.
Every day counts. These free picks are already gaining attention. See them before the crowd does:
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com